2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,995,101 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers In force · High confidence | Iteos Belgium S.A. | In force | High confidence | ||
| Application 16/993,897 | 2-OXO-THIAZOLE Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers Abandoned Abandoned Oct 3, 2022 | Iteos Belgium S.A. | Abandoned | Abandoned Oct 3, 2022 | ||
| Application 17/949,595 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers Abandoned Abandoned Sep 15, 2025 | iTeos Belgium SA | Abandoned | Abandoned Sep 15, 2025 |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Iteos Belgium S.A..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.